title: Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis.
abstract: OBJECTIVE
  Chemotherapy often causes adverse effects, including pain, bloating, diarrhea, and inflammation and ulceration of the mucous membranes lining the digestive tract, which are collectively referred to as mucositis. Unfortunately, no remedy has been found yet to manage these side-effects.
  
  
  RESULTS
  The intestinal glucagon-like peptide-2 (GLP-2) is secreted from the intestinal endocrine L cells after nutrient intake, but recent findings show that the peptide concentration in the plasma also rises after intestinal injury and that GLP-2 receptor activation is crucial for intestinal healing. The antidiabetic hormone GLP-1, cosecreted with GLP-2, diminished mucositis in an animal model of the condition. Therefore, both peptides could be involved in the pathophysiology of mucositis.
  
  
  CONCLUSIONS
  The intestinal GLPs have shown beneficial effects in experimental trials and have potential for therapeutic use. In type 2 diabetic and obese patients, GLP secretion is impaired. Elucidating the role of these endogenous hormones could lead to the identification of mucositis risk factors and an alternative preventive therapy for these patients.
authors: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors: Hannelouise
authors: H
authors: Kissow
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004195:Disease Models, Animal; D052216:Glucagon-Like Peptide 1 / Q000502:physiology / Q000627:therapeutic use*; D053767:Glucagon-Like Peptide 2 / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D052016:Mucositis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D053767:Glucagon-Like Peptide 2; D052216:Glucagon-Like Peptide 1